Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys Labs...

    Dr Reddys Labs relaunches Zenatane-generic version of Accutane in US

    Farhat NasimWritten by Farhat Nasim Published On 2019-06-04T11:52:52+05:30  |  Updated On 4 Jun 2019 11:52 AM IST
    Dr Reddys Labs relaunches Zenatane-generic version of Accutane in US

    Zenatane (lsotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg is being launched with an approved Risk Evaluation and Mitigation Strategy (REMS) Program. The product is a therapeutic equivalent generic version of Accutane.


    New Delhi: Hyderabad-based Dr Reddy's Laboratories Ltd. (Dr Reddy’s) recently announced the relaunch of Zenatane (lsotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg a therapeutic equivalent generic version of Accutane, approved by the U.S. Food and Drug Administration (USFDA).


    Accutane capsule is used to treat severe cystic acne (also known as nodular acne) that has not responded to other treatment.




    The product is being launched with an approved Risk Evaluation and Mitigation Strategy (REMS) Program.


    Explaining about the re-launch, Marc Kikuchi, Chief Executive Officer, North America Generics said, "We're pleased to bring this important product back to the market for the customers and patients who will benefit from access to this medicine and who have had witnessed limited supply and options in the market place."


    "Furthermore, this is important for our company as we have commercialized the first Softgel dosage product from Dr Reddy's own manufacturing plant to ensure consistent and robust supply for this product in the U.S. market, " he added.


    Also Read: Inflated prices to 1000 per cent; Lupin, Sun Pharma, Dr Reddys, others face lawsuit


    The Zenatane (lsotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg brand and generic had U.S. sales of approximately $525 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.


    Dr Reddy's Zenatane (lsotretinoin Capsules, USP) are available in 3x10 (30-count) blister packages of 10 mg, 20 mg 30 mg, and 40 mg Capsules, USP.


    DRL was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India.


    Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddy's offers a portfolio of products and services including APIs, custom
    pharmaceutical services, generics, biosimilars and differentiated formulations. The major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. DRL operates in markets across the globe.


    Also Read: Dr Reddys launches Tadalafil tablets for treating erectile dysfunction



    AccutaneacneCardiovascularcystic acneDermatologydiabetologyDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsDRLgastrointestinalHyderabadlsotretinoinlsotretinoin Capsulesnodular acneoncologyREMSRisk evaluationsevere acneUS marketUSFDAZenatane

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok